BACKGROUND: Lung disease is the leading cause of death in systemic sclerosis (SSc). The diagnosis of SSc-related lung disease (SSc-LD) is often a contraindication to lung transplantation (LT) due to concerns that extrapulmonary involvement will yield worse outcomes. We sought to evaluate posttransplantation outcomes in persons with SSc-LD with esophageal involvement compared with persons with nonconnective tissue disease-related interstitial lung disease (nCTD-ILD). METHODS: From 1998 to 2012, persons undergoing LT for SSc-LD were age and gender matched in a 2:1 fashion to controls undergoing LT for nCTD-ILD. Esophageal function was assessed by pH testing and manometry. We defined esophageal dysfunction as the presence of a DeMeester score >14 or dysmotility more severe than "mild nonspecific disorder". The primary outcome was posttransplantation survival. Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of acute rejection. Survival and fBOS were estimated with Kaplan-Meier methods. Acute rejection was compared with Student's t test. RESULTS: Survival was similar in 23 persons with SSc-LD and 46 controls who underwent LT (P = 0.47). For the SSc-LD group, 1- and 5-year survival was 83% and 76% compared with 91% and 64% in the nCTD-ILD group, respectively. There were no differences in fBOS (P = 0.83). Rates of acute rejection were less in SSc-ILD (P = 0.05). Esophageal dysfunction was not associated with worse outcomes (P>0.55). CONCLUSIONS: Persons with SSc-LD appear to have similar survival and fBOS as persons transplanted for nCTD-ILD. The risk of acute rejection after transplantation may be reduced in persons with SSc-LD. Esophageal involvement does not appear to impact outcomes.
BACKGROUND:Lung disease is the leading cause of death in systemic sclerosis (SSc). The diagnosis of SSc-related lung disease (SSc-LD) is often a contraindication to lung transplantation (LT) due to concerns that extrapulmonary involvement will yield worse outcomes. We sought to evaluate posttransplantation outcomes in persons with SSc-LD with esophageal involvement compared with persons with nonconnective tissue disease-related interstitial lung disease (nCTD-ILD). METHODS: From 1998 to 2012, persons undergoing LT for SSc-LD were age and gender matched in a 2:1 fashion to controls undergoing LT for nCTD-ILD. Esophageal function was assessed by pH testing and manometry. We defined esophageal dysfunction as the presence of a DeMeester score >14 or dysmotility more severe than "mild nonspecific disorder". The primary outcome was posttransplantation survival. Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of acute rejection. Survival and fBOS were estimated with Kaplan-Meier methods. Acute rejection was compared with Student's t test. RESULTS: Survival was similar in 23 persons with SSc-LD and 46 controls who underwent LT (P = 0.47). For the SSc-LD group, 1- and 5-year survival was 83% and 76% compared with 91% and 64% in the nCTD-ILD group, respectively. There were no differences in fBOS (P = 0.83). Rates of acute rejection were less in SSc-ILD (P = 0.05). Esophageal dysfunction was not associated with worse outcomes (P>0.55). CONCLUSIONS:Persons with SSc-LD appear to have similar survival and fBOS as persons transplanted for nCTD-ILD. The risk of acute rejection after transplantation may be reduced in persons with SSc-LD. Esophageal involvement does not appear to impact outcomes.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: Jonathan B Orens; Marc Estenne; Selim Arcasoy; John V Conte; Paul Corris; Jim J Egan; Thomas Egan; Shaf Keshavjee; Christiane Knoop; Robert Kotloff; Fernando J Martinez; Steven Nathan; Scott Palmer; Alec Patterson; Lianne Singer; Gregory Snell; Sean Studer; J L Vachiery; Allan R Glanville Journal: J Heart Lung Transplant Date: 2006-07 Impact factor: 10.247
Authors: Frank D'Ovidio; Lianne G Singer; Denis Hadjiliadis; Andrew Pierre; Thomas K Waddell; Marc de Perrot; Micheal Hutcheon; Linda Miller; Gail Darling; Shaf Keshavjee Journal: Ann Thorac Surg Date: 2005-10 Impact factor: 4.330
Authors: Angela Pakozdi; Svetlana Nihtyanova; Pia Moinzadeh; Voon H Ong; Carol M Black; Christopher P Denton Journal: J Rheumatol Date: 2011-08-15 Impact factor: 4.666
Authors: Malek G Massad; Charles R Powell; Jacques Kpodonu; Cimenga Tshibaka; Ziad Hanhan; Norman J Snow; Alexander S Geha Journal: World J Surg Date: 2005-11 Impact factor: 3.352
Authors: Marco G Patti; Marcelo F Vela; David D Odell; Joel E Richter; P Marco Fisichella; Michael F Vaezi Journal: J Laparoendosc Adv Surg Tech A Date: 2016-05-24 Impact factor: 1.878
Authors: Ryan M Kern; Jonathan P Singer; Laura Koth; Joshua Mooney; Jeff Golden; Steven Hays; John Greenland; Paul Wolters; Emily Ghio; Kirk D Jones; Lorriana Leard; Jasleen Kukreja; Paul D Blanc Journal: Chest Date: 2015-06 Impact factor: 9.410
Authors: Alicia M Hinze; Cheng T Lin; Amira F Hussien; Jamie Perin; Aida Venado; Jeffrey A Golden; Francesco Boin; Robert H Brown; Robert A Wise; Fredrick M Wigley Journal: Rheumatology (Oxford) Date: 2020-04-01 Impact factor: 7.580
Authors: Catherine H Miele; Kristin Schwab; Rajeev Saggar; Erin Duffy; David Elashoff; Chi-Hong Tseng; Sam Weigt; Deepshikha Charan; Fereidoun Abtin; Jimmy Johannes; Ariss Derhovanessian; Jeffrey Conklin; Kevin Ghassemi; Dinesh Khanna; Osama Siddiqui; Abbas Ardehali; Curtis Hunter; Murray Kwon; Reshma Biniwale; Michelle Lo; Elizabeth Volkmann; David Torres Barba; John A Belperio; David Sayah; Thomas Mahrer; Daniel E Furst; Suzanne Kafaja; Philip Clements; Michael Shino; Aric Gregson; Bernard Kubak; Joseph P Lynch; David Ross; Rajan Saggar Journal: Ann Am Thorac Soc Date: 2016-06